The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q co-deletion, ATRX mutation, TERT mutations, and MGMT methylation. The gene discussed is IDH2; the disease is brain neoplasm.